Isthmus Partners’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.66M Sell
39,357
-2,123
-5% -$188K 0.38% 65
2025
Q4
$3.33M Sell
41,480
-536
-1% -$44.9K 0.37% 70
2025
Q3
$4.1K Buy
42,016
+7,848
+23% +$632K ﹤0.01% 148
2025
Q2
$2.38M Buy
34,168
+2,547
+8% +$145K 0.28% 89
2025
Q1
$1.57M Buy
31,621
+3,330
+12% +$211K 0.2% 101
2024
Q4
$1.98M Buy
28,291
+507
+2% +$42.1K 0.24% 99
2024
Q3
$2.91M Sell
27,784
-5,486
-16% -$642K 0.35% 79
2024
Q2
$4.73M Buy
33,270
+15,507
+87% +$1.79M 0.56% 52
2024
Q1
$1.98M Buy
+17,763
New +$2.12M 0.22% 105

Other funds holding ACLS

Isthmus Partners's ACLS Position: Q1 2026 in Review

Isthmus Partners reduced its Axcelis (ACLS) stake by 5.1% in Q1 2026, selling an estimated $188K and leaving 39,357 shares worth $3.66M. The position accounts for 0.38% of the portfolio, ranked #65.

Isthmus Partners first reported a position in ACLS in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.73M in Q2 2024. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • Isthmus Partners held 39,357 shares of Axcelis worth $3.66M as of Q1 2026.
  • Isthmus Partners sold 2,123 Axcelis shares in Q1 2026, an estimated $188K.
  • Axcelis made up 0.38% of Isthmus Partners's portfolio in Q1 2026, its #65 holding.
  • Isthmus Partners first reported a position in Axcelis in Q1 2024 and has held it in 9 quarters since.
  • Isthmus Partners's Axcelis position peaked at $4.73M in Q2 2024.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on Isthmus Partners's 13F filing for Q1 2026, filed 30 Apr 2026.